OTCMKTS:IPSEY Ipsen (IPSEY) Stock Forecast, Price & News $29.72 0.00 (0.00%) (As of 06/7/2023 ET) Add Compare Share Share Today's Range$29.72▼$29.7250-Day Range$27.50▼$30.8852-Week Range$21.17▼$31.18Volume110 shsAverage Volume704 shsMarket CapitalizationN/AP/E RatioN/ADividend Yield0.77%Price Target$107.22 ProfileProfileAnalyst RatingsChartCompetitorsDividendHeadlinesShort InterestProfileAnalyst RatingsChartCompetitorsDividendHeadlinesShort Interest Ipsen MarketRank™ ForecastAnalyst RatingHold2.30 Rating ScoreUpside/Downside260.8% Upside$107.22 Price TargetShort InterestBearishDividend StrengthWeakBased on Four FactorsSustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings Growth2.87%From $2.44 to $2.51 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.99 out of 5 stars 3.2 Analyst's Opinion Consensus RatingIpsen has received a consensus rating of Hold. The company's average rating score is 2.30, and is based on 3 buy ratings, 7 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $107.22, Ipsen has a forecasted upside of 260.8% from its current price of $29.72.Amount of Analyst CoverageIpsen has received no research coverage in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares ShortedShort Interest Ratio / Days to CoverIpsen has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Ipsen has recently increased by 52.63%, indicating that investor sentiment is decreasing significantly. Previous Next 0.8 Dividend Strength Dividend YieldIpsen has a dividend yield of 0.79%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthIpsen does not have a long track record of dividend growth.Dividend SustainabilityBased on earnings estimates, Ipsen will have a dividend payout ratio of 9.16% next year. This indicates that Ipsen will be able to sustain or increase its dividend. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IPSEY. Previous Next 2.4 News and Social Media Coverage News SentimentIpsen has a news sentiment score of 1.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies. Previous Next N/A Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ipsen insiders have not sold or bought any company stock. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Ipsen are expected to grow by 2.87% in the coming year, from $2.44 to $2.51 per share.Price to Book Value per Share RatioIpsen has a P/B Ratio of 3.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Ipsen (OTCMKTS:IPSEY) StockIpsen SA manufactures pharmaceutical products for oncology, neuroscience, and rare diseases. It operates through the following segments: Specialty Care. The Specialty Care segment focuses on oncology with Somatuline, a somatostatin analog for the treatment of neuroendocrine tumors; Cabometyx, the single-agent treatment with significant improvement across all key efficacy endpoints in second-line renal cell carcinoma; Onivyde, a differentiated product with overall survival benefit addressing a high unmet medical need in pancreatic cancer; and Decapeptyl, an established and growing product in Europe and China for prostate cancer and rare diseases with Nutropin, a liquid formulation of recombinant human growth hormone and Increlex, a recombinant insulin-like growth factor of human origin. The company was founded by Henri Beaufour in 1929 and is headquartered in Boulogne-Billancourt, France.Read More Receive IPSEY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ipsen and its competitors with MarketBeat's FREE daily newsletter. Email Address IPSEY Stock News HeadlinesJune 1, 2023 | americanbankingnews.comIpsen S.A. (OTCMKTS:IPSEY) Increases Dividend to $0.23 Per ShareJune 1, 2023 | finance.yahoo.comIpsen SA initiates a share buy-back program to cover its free employee share-allocation planJune 8, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.June 1, 2023 | finance.yahoo.comIpsen SA initiates a share buy-back program to cover its free employee share-allocation planMay 31, 2023 | finance.yahoo.comIpsen S.A. - Combined Shareholders’ Meeting of Ipsen S.A. held on 31 May 2023May 31, 2023 | marketwatch.comIpsen Seeks Shareholders' Approval for $1.80 Billion BuybackMay 31, 2023 | markets.businessinsider.comIPSEN Issues Regulatory Framework Of Share Repurchase Program - Quick FactsMay 28, 2023 | americanbankingnews.comIpsen (OTCMKTS:IPSEY) Shares Pass Above Two Hundred Day Moving Average of $27.98June 8, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.May 26, 2023 | finance.yahoo.comIpsen receives CHMP negative opinion, following re-examination of potential first FOP treatment in the E.U.May 25, 2023 | seekingalpha.comIPSEY Ipsen S.A.May 20, 2023 | finanznachrichten.deIpsen Pharma: Ipsen delivers a strong sales performance in the first quarter of 2022May 19, 2023 | finance.yahoo.comHealth Canada approves Ipsen’s Sohonos (palovarotene capsules) as the first approved treatment for fibrodysplasia ossificans progressivaMay 19, 2023 | finance.yahoo.comIpsen receives positive opinion in Europe for Dysport® in the management of urinary incontinence in adults with neurogenic detrusor overactivity due to multiple sclerosis or spinal cord injuryMay 19, 2023 | finance.yahoo.comIpsen to acquire exclusive rights to investigational ERK inhibitor as part of its existing research collaboration with AGV DiscoveryMay 18, 2023 | finance.yahoo.comIpsen and Marengo Therapeutics announce strategic partnership to advance two precision immuno-oncology candidates from Marengo’s STAR Platform into the clinicMay 10, 2023 | finance.yahoo.comIpsen : 2023 CSM - Formalities for making available preparatory documents to the MeetingMay 3, 2023 | marketwatch.comIRLAB Comments on Statements in Ipsen's 2022 Universal Registration Document and the Further Development of MesdopetamApril 27, 2023 | finanznachrichten.deIpsen Pharma: Ipsen delivers robust sales growth in the first quarter of 2023 and confirms its full-year guidanceApril 27, 2023 | finance.yahoo.comIpsen delivers robust sales growth in the first quarter of 2023 and confirms its full-year guidanceApril 26, 2023 | americanbankingnews.comBrokerages Set Ipsen S.A. (OTCMKTS:IPSEY) PT at $109.88April 25, 2023 | finanznachrichten.deIpsen Pharma: Ipsen appoints Sandra Silvestri as EVP, Chief Medical Officer and Head of Global Medical Affairs, Patient Safety and Patient AffairsApril 24, 2023 | finance.yahoo.comIpsen appoints Sandra Silvestri as EVP, Chief Medical Officer and Head of Global Medical Affairs, Patient Safety and Patient AffairsApril 18, 2023 | americanbankingnews.comShort Interest in Ipsen S.A. (OTCMKTS:IPSEY) Rises By 25.0%April 12, 2023 | wsj.comIpsen’s Deal-Making Ability to Get Boost From Market Normalization — InterviewApril 6, 2023 | finance.yahoo.comIpsen S.A. publishes its 2022 Universal registration documentApril 6, 2023 | bloomberg.comIpsen Hunts For Targets With $4.4 Billion to Spend, CEO SaysSee More Headlines IPSEY Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IPSEY Company Calendar Ex-Dividend for 6/27 Dividend6/02/2023Today6/08/2023Dividend Payable6/27/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS Industry Diagnostic substances Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:IPSEY CUSIPN/A CIKN/A Webwww.ipsen.com Phone(315) 833-5000Fax33-01-58-33-50-01Employees5,700Year FoundedN/APrice Target and Rating Average Stock Price Forecast$107.22 High Stock Price Forecast$142.00 Low Stock Price Forecast$86.00 Forecasted Upside/Downside+260.8%Consensus RatingHold Rating Score (0-4)2.30 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio1.80 Quick Ratio1.58 Sales & Book Value Annual Sales$3.33 billion Price / SalesN/A Cash Flow$3.51 per share Price / Cash Flow8.46 Book Value$9.72 per share Price / Book3.06Miscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta0.99 Key ExecutivesDavid G. LoewChief Executive Officer & DirectorAymeric Le ChatelierChief Financial Officer & Executive Vice PresidentAidan MurphyExecutive Vice President-Technical OperationsHoward MayerExecutive Vice President-Research & DevelopmentSandra SilvestriChief Medical Officer & Executive Vice PresidentKey CompetitorsARCA biopharmaNASDAQ:ABIOBG MedicineOTCMKTS:BGMDHemagen DiagnosticsOTCMKTS:HMGNResponse GeneticsOTCMKTS:RGDXQ[email protected] TechnologyOTCMKTS:LPTCView All Competitors IPSEY Stock - Frequently Asked Questions Should I buy or sell Ipsen stock right now? 10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ipsen in the last year. There are currently 7 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" IPSEY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IPSEY, but not buy additional shares or sell existing shares. View IPSEY analyst ratings or view top-rated stocks. What is Ipsen's stock price forecast for 2023? 10 Wall Street analysts have issued twelve-month price objectives for Ipsen's shares. Their IPSEY share price forecasts range from $86.00 to $142.00. On average, they expect the company's share price to reach $107.22 in the next twelve months. This suggests a possible upside of 260.8% from the stock's current price. View analysts price targets for IPSEY or view top-rated stocks among Wall Street analysts. How have IPSEY shares performed in 2023? Ipsen's stock was trading at $26.88 at the beginning of 2023. Since then, IPSEY stock has increased by 10.6% and is now trading at $29.72. View the best growth stocks for 2023 here. Are investors shorting Ipsen? Ipsen saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 2,900 shares, an increase of 52.6% from the April 30th total of 1,900 shares. Based on an average daily volume of 900 shares, the short-interest ratio is presently 3.2 days. View Ipsen's Short Interest. How often does Ipsen pay dividends? What is the dividend yield for Ipsen? Ipsen declared a dividend on Thursday, June 1st. Stockholders of record on Monday, June 5th will be paid a dividend of $0.2337 per share on Tuesday, June 27th. This represents a dividend yield of 0.8%. The ex-dividend date of this dividend is Friday, June 2nd. This is a positive change from the stock's previous dividend of $0.23. Read our dividend analysis for IPSEY. Is Ipsen a good dividend stock? Ipsen (OTCMKTS:IPSEY) pays an annual dividend of $0.23 per share and currently has a dividend yield of 0.79%. Read our dividend analysis for IPSEY. What is Ipsen's stock symbol? Ipsen trades on the OTCMKTS under the ticker symbol "IPSEY." How do I buy shares of Ipsen? Shares of IPSEY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Ipsen's stock price today? One share of IPSEY stock can currently be purchased for approximately $29.72. How many employees does Ipsen have? The company employs 5,700 workers across the globe. How can I contact Ipsen? Ipsen's mailing address is 65 quai Georges Gorse, Boulogne-Billancourt cedex I0, 92650. The official website for the company is www.ipsen.com. The company can be reached via phone at (315) 833-5000, via email at investor.relations@ipsen.com, or via fax at 33-01-58-33-50-01. This page (OTCMKTS:IPSEY) was last updated on 6/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ipsen S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.